文献速递产科母胎医学

非RhD红细胞同种免疫的产前诊断与管理

The Diagnosis and Prenatal Management of Non-RHD Alloimmunizations.
PubMed 文献 · Prenat Diagn · 2026-08-05

本文综述非RhD红细胞同种免疫的产前诊断与风险评估策略。RhD以外抗体(Rh c/C/E、Kell、Kidd、Duffy、MNS等)所致胎儿贫血风险不一,且占比渐增;现有诊疗框架多源自RhD同种免疫,但在抗体滴定阈值、无创胎儿抗原基因分型准确性及干预时机上存在重要差异,需抗体特异性个体化管理。

要点

  • 非RhD抗体(Rh c/C/E、Kell、Kidd、Duffy、MNS)可致胎儿贫血,需专门产前评估。
  • 多数诊疗流程基于RhD证据外推,抗体滴定阈值与干预时机存在差异。
  • 无创胎儿抗原基因分型有助于风险分层,但非RhD抗体准确性不同。

核心结论

  • 非RhD同种免疫需按抗体特异性制定产前诊断与管理路径,不能完全照搬RhD方案。
  • 无创诊断技术进步改善了风险分层,但个体化诊疗路径仍待建立。

研究设计与样本

  • 本文为综述,聚焦非RhD红细胞同种免疫妊娠的产前诊断与风险评估策略。

主要发现

  • RhD免疫预防实施后RhD同种免疫显著减少,但仍是妊娠同种免疫的主要原因。
  • Rh c、C、E及Kell、Kidd、Duffy、MNS系统抗体与程度不一的胎儿贫血风险相关,占需专科产前保健病例比例渐增。
  • 非RhD抗体在抗体滴定临界阈值、无创胎儿抗原基因分型诊断准确性及胎儿新生儿干预风险与时机上与RhD存在重要差异。

临床怎么用

  • 对非RhD同种免疫妊娠应进行抗体特异性风险评估,并据此制定个体化产前管理方案。
  • 应用无创胎儿抗原基因分型与抗体滴定辅助风险分层,但需注意非RhD抗体的阈值与准确性差异。

局限性

  • 多数诊断算法与管理方案基于RhD同种免疫证据外推,非RhD抗体特异性证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Red blood cell (RBC) alloimmunization remains a relevant cause of hemolytic disease of the fetus and newborn (HDFN). Although RhD immunization has significantly decreased since the implementation of systematic prophylaxis, it is still the main cause of alloimmunization in pregnancy. Clinically significant non-RhD alloantibodies, particularly those of the Rh (c, C, E), Kell, Kidd, Duffy, and MNS systems, are associated with variable risk of fetal anemia and account for an increasing proportion of alloimmunized pregnancies requiring specialized prenatal care. Most diagnostic algorithms and management protocols are based on evidence derived from RhD alloimmunization. Although these frameworks are often extrapolated to other alloantibodies, important differences exist regarding antibody titration and critical thresholds, the diagnostic accuracy of non-invasive fetal antigen genotyping, and the risk and timing of fetal and neonatal interventions. These differences underscore the need for antibody-specific considerations in the prenatal diagnosis and management of non-RhD alloimmunization. Though advances in non-invasive diagnostic techniques have improved risk stratification and optimized prenatal management, individualized care pathways in alloimmunized pregnancies are needed. This review will focus on the current strategies for prenatal diagnosis and risk assessment in pregnancies complicated by non-RhD red cell alloimmunization.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Bennasar M, Borrell A. The Diagnosis and Prenatal Management of Non-RHD Alloimmunizations. Prenat Diagn. 2026. PMID: 42555973. doi:10.1002/pd.70231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。